The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The consideration for the medicines in India is valued at Rs 180.48 crore
Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.
The AI-infused solution enables radiologists by fast triaging abnormalities in X-ray, annotating and automatic report generation with significantly improved performance
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Subscribe To Our Newsletter & Stay Updated
